JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schechter, N. R.
Right arrow Articles by Ang, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schechter, N. R.
Right arrow Articles by Ang, K. K.
Journal of Nuclear Medicine Vol. 45 No. 10 1683-1687
© 2004 by Society of Nuclear Medicine

Clinical Investigations

Radiation Dosimetry of 99mTc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck

Naomi R. Schechter, MD1, Richard E. Wendt, III, PhD2, David J. Yang, PhD2, Ali Azhdarinia, MS2, William D. Erwin, MS2, Anne M. Stachowiak, AAS2, Lyle D. Broemeling, PhD3, E. Edmund Kim, MD2, James D. Cox, MD1, Donald A. Podoloff, MD2 and K. Kian Ang, MD, PhD1

1 Division of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
2 Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas
3 Division of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas

This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging. Methods: Whole-body scanning was performed on 6 patients with head and neck squamous cell carcinoma up to 24 h after administration of 99mTc-EC-C225. Alternate patients who had been randomized to receive C225 in a phase III trial received 99mTc-EC-C225 before their 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6, respectively). Radiation dosimetry was assessed using the MIRD method. Results: The critical organ was the kidney, with an average radiation-absorbed dose for all 6 patients of 0.0274 mGy/MBq. The average total-body absorbed dose was 0.0022 mGy/MBq (0.243 cGy/1,110 MBq). Conclusion: The new radiopharmaceutical 99mTc-EC-C225 appears to have reasonable dosimetric properties for a diagnostic nuclear medicine agent. Correlation of the imaging results with clinical findings is the next step.

Key Words: epidermal growth factor receptor • dosimetry • imaging • technetium • C225


Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  



This article has been cited by other articles:


Home page
 JNMHome page
I. Velikyan, A. L. Sundberg, O. Lindhe, A. U. Hoglund, O. Eriksson, E. Werner, J. Carlsson, M. Bergstrom, B. Langstrom, and V. Tolmachev
Preparation and Evaluation of 68Ga-DOTA-hEGF for Visualization of EGFR Expression in Malignant Tumors
J. Nucl. Med., November 1, 2005; 46(11): 1881 - 1888.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.